BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target
BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.
A stock expert named Thomas Shrader still thinks Opus Genetics is a good company and believes it could be worth $12 per share. When smart analysts keep believing in a company, it's a sign they think the business is doing well and will keep doing well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.